Search results
Results From The WOW.Com Content Network
Affinity describes how well a drug can bind to a receptor. Faster or stronger binding is represented by a higher affinity, or equivalently a lower dissociation constant. The EC 50 should not be confused with the affinity constant, K d. While the former reflects the drug concentration needed for a level of tissue response, the latter reflects ...
The binding constant, or affinity constant/association constant, is a special case of the equilibrium constant K, [1] and is the inverse of the dissociation constant. [2] It is associated with the binding and unbinding reaction of receptor (R) and ligand (L) molecules, which is formalized as: R + L ⇌ RL
An example drug affinity responsive target stability (DARTS) workflow. Binding of a drug to a protein often leads to ligand-induced stabilization of the protein. In DARTS, drug and control treated proteins are subjected to limited proteolysis and the extent of protein digestion can either be visualized on a gel or measured by mass spectrometry .
The resource is maintained by the University of North Carolina at Chapel Hill and is funded by the NIMH Psychoactive Drug Screening Program and by a gift from the Heffter Research Institute. As of April 2010 [update] , the database had data for 7 449 compounds at 738 different receptors and, as of 27 April 2018 [update] , 67 696 K i values.
Intrinsic activity (IA) and efficacy (E max) refer to the relative ability of a drug-receptor complex to produce a maximum functional response. This must be distinguished from the affinity, which is a measure of the ability of the drug to bind to its molecular target, and the EC 50, which is a measure of the potency of the drug and which is proportional to both efficacy and affinity.
The phrase "drug design" is similar to ligand design (i.e., design of a molecule that will bind tightly to its target). [6] Although design techniques for prediction of binding affinity are reasonably successful, there are many other properties, such as bioavailability, metabolic half-life, and side effects, that first must be optimized before a ligand can become a safe and effictive drug.
In general, high-affinity ligand binding results from greater attractive forces between the ligand and its receptor while low-affinity ligand binding involves less attractive force. In general, high-affinity binding results in a higher occupancy of the receptor by its ligand than is the case for low-affinity binding; the residence time ...
Avidity (functional affinity) is the accumulated strength of multiple affinities. [2] For example, IgM is said to have low affinity but high avidity because it has 10 weak binding sites for antigen as opposed to the 2 stronger binding sites of IgG, IgE and IgD with higher single binding affinities. [citation needed]